Third Harmonic Bio
THRD
THRD was delisted on the 30th of July, 2025.
62 hedge funds and large institutions have $416M invested in Third Harmonic Bio in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
72% more capital invested
Capital invested by funds: $241M → $416M (+$174M)
11% more funds holding
Funds holding: 56 → 62 (+6)
0.37% more ownership
Funds ownership: 93.59% → 93.95% (+0.37%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.49M |
| 2 |
JP Morgan Chase
New York
|
+$7.93M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.88M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$2.1M |
| 5 |
BlackRock
New York
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$11.5M |
| 2 |
CC
Commodore Capital
New York
|
-$7.87M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$2.68M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.92M |
| 5 |
ACM
Atika Capital Management
New York
|
-$1.3M |
THRD Hedge Fund Activity: Q4 2023 in Review
62 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q4 2023, worth a combined $416M — up 72% from $241M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new THRD positions and 8 closed out — a net gain of 6 holders — while 26 added to existing stakes and 13 trimmed.
The largest buyer was RA Capital Management, adding an estimated $8.49M. The largest seller was Tang Capital Management, exiting entirely with an estimated $11.5M sold.
- 62 institutional investors held Third Harmonic Bio (THRD) as of Q4 2023, up from 56 in Q3 2023.
- Funds reported $416M of Third Harmonic Bio stock for Q4 2023, up 72% quarter-over-quarter.
- 14 funds opened new Third Harmonic Bio positions in Q4 2023 and 8 closed out, a net change of +6 holders.
- The largest Third Harmonic Bio buyer in Q4 2023 was RA Capital Management, an estimated $8.49M added.
- The largest Third Harmonic Bio seller in Q4 2023 was Tang Capital Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2023.